Site Meter

Wednesday, March 3, 2010

Pfizer, Medivation’s Dimebon Connection Study Fails (Alzheimer’s Clinical Trial)


This is surely devastating news for the Alzheimer's community because the expectations for Dimebon were running very high.....
By Bob DeMarco
Alzheimer's Reading Room

Editor Note: If you or your loved one are enrolled in a Dimebon clinical trial, I would be interested in your reaction to the news. Please use the comments box below this article.

Pfizer Inc. (PFE) and Medivation Inc. (MDVN) announced today that Dimebon, their experimental drug for Alzheimer’s disease, failed to benefit patients in an advanced study. The clinical trial, called the Connection study, included almost 600 patients with mild-to-moderate Alzheimer’s disease.

MDVN dropped about 69 percent on the news.

For those of you emailing me or asking, as of right now the status of the Dimebon clinical trial that Mom is enrolled in has not changed. The status of the other three ongoing Dimebon phase 3 clinical trials has not changed at this time.

My mother is enrolled in the severe trial and the adjunct drug is Namenda. So Mom is currently on the combination of Namenda and Dimebon.

This is surely devastating news for the Alzheimer's community because the expectations for Dimebon were running very high.

As I mentioned previously, I will not be commenting on the effect that Dimebon has on my mother until the end of 26 week trial period.

Also see Pfizer, Medivation’s Drug Fails in Alzheimer’s Study (Update 3)



Subscribe to the Alzheimer's Reading Room
Enter Your Email Address


More About the Alzheimer's Reading Room
I Remember Better When I Paint: Treating Alzheimer's through the Creative Arts
"I Remember Better When I Paint"

Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,200 articles with more than 9,000 links on the Internet. Bob resides in Delray Beach, FL.

Original content Bob DeMarco, the Alzheimer's Reading Room